The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Brufsky Spotlights Data With Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
July 20th 2020Adam M. Brufsky, MD, PhD, further discusses the utility of trastuzumab deruxtecan in HER2-positive breast cancer, ongoing research efforts examining the antibody–drug conjugate, and how he approaches sequencing in the paradigm.
Adjuvant T-DM1/Pertuzumab Combo Misses iDFS End Point in High-Risk HER2-Positive Breast Cancer
Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.
Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer
July 13th 2020William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.
Systemic Therapies Improve Breast Cancer With Brain Metastases Management
July 7th 2020Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival for these patients, and a number of agents on the horizon.
Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases
July 6th 2020Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.
FDA Approves Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer
The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer
June 23rd 2020The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.